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More famously, Doudna and Charpentier first filed their fundamental patent application covering CRISPR-Cas9 on May 25, 2012.
8 Their original patent application contained over 150 claims-particular ways to practice the invention that defined the application's boundaries-and was notably unspecific with respect to cell type. 9 Nonetheless, Doudna and Charpentier's patent attorneys pegged their clients' invention broadly, as the use of a single-guide RNA to mediate the editing of genomic DNA. 10 It was the ease, flexibility, and precision of this advance that has largely thrust CRISPR into the lay lexicon. During the pendency of Doudna and Charpentier's application in the USA, Zhang also filed a U.S. patent application-directed specifically to eukaryotic applications of CRISPR-Cas9. 12 The principal improvement of Zhang's methods over his predecessors was the use of a nuclear localization signal and, separately, codon optimization to natively express Cas9.
13 But Zhang's attorneys fast tracked his application through the U.S.P.T.O., a relatively expensive and strategically risky process.
14 As a consequence, Zhang's patent-even though it was filed after applications from Doudna, Charpentier, andŠikšnys-was issued first in the USA. 15 That quandary gave rise to the now-famous patent dispute in the USA, the first round of which was won by Zhang. 16 The remainder of it is still being appealed; a decision is expected in late 2018. 17 The U.S. interference decision, however, stands apart from the rest of the world. As detailed-excellently-by Knut Jørgen Egelie and his colleagues at Norwegian University of Science and Technology-the global CRISPR patent landscape is varied. 18 Europe has now officially sided with Doudna and Charpentier over Zhang, although opposition proceedings at the European Patent Office have just begun. 19 And China, too, recently sided with Doudna and Charpentier. 20 These conflicting decisions are further complicated by a set of interlocking license agreements from the inventors' biotech companies, with a great deal of uncertainty playing out in the global commercial sector for CRISPR. 21 Unraveling those agreements, and the issues raised by the patenting of the technology in the first instance, speaks volumes about the values and pitfalls of patents in the research enterprise.
INTERINSTITUTIONAL COLL ABORATION
One notable aspect of the CRISPR patent dispute is that it is, by and large, a dispute between academic research institutions. It pits lawyers representing the University 568 r Patent protection for CRISPR of California against lawyers representing the Broad Institute of MIT and Harvard. 22 To be sure, university rivalries are common. 23 But because universities share among themselves a larger mission to create and disseminate knowledge to the public, litigiousness among them has been historically rare. 24 University-against-university patent disputes, like CRISPR, complicate interinstitutional research agreements on several levels. First, they have the potential to chill formal interinstitutional research collaborations among universities if the institutions cannot agree on intellectual property issues beforehand. 25 Universities may simply be unwilling to enter into such agreements in the first instance, or, perhaps more perniciously, discourage their faculty from informally developing such networks. 26 While the empirical evidence for such a diminishment in collaborative efforts is slight-difficult to demonstrate, in part, because it requires the proof of opportunities not taken by universities-some recent survey data have found that 'institutionally mandated [materials transfer agreements] put sand in the wheels of a lively system of intra-disciplinary exchanges of research tools'. 27 Aside from this, there is substantial anecdotal evidence of institutional difficulties in creating such agreements.
28 It stands to reason that, at least in some instances, these difficulties have ended some collaborations before they could begin. More immediately, this is a current issue with the CRISPR patent dispute given some internal dissention between Doudna and Charpentier's respective institutions concerning the intellectual property involved. Although Doudna and Charpentier filed their joint patent application in 2012, their institutions did not formally assent to a cross-licensing agreement until December 2016. 29 agreement for a single piece of technology has proved difficult, it is unclear how the two institutions will deal with one another on future collaborations. Second, even with some friction between universities over obtaining patents for their researchers' work, it has been rare for universities to sue one another regarding inventorship-until now. In 2011, for instance, the University of Utah sued the MaxPlanck Institute concerning inventorship over a foundational group of patents concerning RNA interference technology. 30 And since 2012, Stanford University and the Chinese University of Hong Kong have battled one another over lucrative patent rights to noninvasive prenatal genetic diagnostics.
31 That dispute-despite several rounds of appeals-is still ongoing.
32 Such patent disputes are costly, high stakes, and high profile. And while the CRISPR patent dispute itself is not a cause of such conflict, it has become emblematic-and potentially prophetic-of the tenor of such disputes today. Avoiding them in the first instance is a sensible institutional priority. But that sometimes comes at the cost of avoiding one's colleagues. 33 Third, even apart from the administrative institutional level, patent disputes like these damper the culture of scientific collaboration, clearly something of tremendous import to modern science. 34 Putting a price on a loosely defined culture of scientific collaboration is difficult-its loss is difficult to quantify. Nonetheless, many of the most significant breakthroughs of the past century arose in part from a culture of scientific openness and collegiality. 35 Abandoning that in favor of inuring patent rights to researchers from a single institution seems, at best, unwise. Relatedly, it may erode scientists' penchant for honest, if critical assessments, of their own work among collaborators and colleagues. A key piece of evidence used in the U.S. CRISPR patent interference against the University of California was a single one of Doudna's public statements that her collaborators 'weren't sure if CRISPR/Cas9 would work in eukaryotes-plant and animal cells'. 36 That statement has now echoed throughout laboratories across the USA as a cautionary tale against critical reflections of one's work-at least while patents are pending. Lastly, patent conflicts' hindrance of interinstitutional collaborations may simply be costly. Today, some research benefits from economies of scale, such as where expensive equipment can be shared among institutions. 38 The New York Genome Center, for example, is a joint venture among several New York-area research institutions: NYU, Columbia, Cold Spring Harbor Laboratories, to name a few. 39 This arrangement allows researchers at these institutions to share a fleet of Illumina X Ten sequencers, the total cost of which-including operations-runs into the millions of US dollars. 40 Where research funding is diminishing-as is sadly the case in much of the Anglophone world 41 -universities may foolishly hesitate to engage in similar cost-saving arrangements in the short-sighted hope of avoiding future patent lawsuits. 42 One would hope that the CRISPR patent dispute teaches others that such myopia isn't warranted.
SURROGATE LICENSING
Interinstitutional tensions aside, the CRISPR patent dispute raises some significant issues concerning patent licensing and commercialization-agreements between universities and commercial entities over the use and development of CRISPR. In CRISPR's case, both the Broad Institute and the University of California have employed a system of 'surrogate licensing': 'outsourc[ing] the licensing and commercialization of a valuable patent portfolio to a private company'. 43 It is that company-rather than university-that takes responsibility for licensing the included patents to commercial researchers, including biotech startups and large pharmaceutical developers. 44 At the same time, the surrogate is frequently working to develop the technology itself. 45 This is certainly true for CRISPR. The University of California has delegated the entirety of its licensing rights to Doudna's inventions to Caribou Biosciences, which in turn has granted an exclusive license to develop human therapies to Intellia Therapeutics. 46 The Broad Institute, meanwhile, has employed Editas Medicine as its surrogate for human therapeutics; the institute retains control over non-commercial and ('But this [was] an absolutely true statement that any good scientist would say even if they believed CRISPR would work in eukaryotic cells. . . . Is this the lesson we really want to learn from CRISPR? That scientists working in fields with commercial potential should never speak honestly about their work and the scientific process?'). 38 43 Contreras & Sherkow, supra note 21 , at 698. 44 Id. at 698-99. 45 Id. 46 Id. non-human therapy uses. 47 Surrogates, therefore, 'control a large and lucrative field for the exploitation of the licensed technology, and have significant freedom both to exploit it themselves and seek partners and sublicenses '. 48 This system of surrogate licensing-while not unique to CRISPR-sets up several obvious conflicts. Surrogates may very well be unwilling to sublicense their technology to smaller biotech companies-who, in a very real sense, are rivals to the surrogate. 49 Smaller companies seeking to develop similar uses of CRISPR to that studied by, say, Editas are unlikely to receive patent licenses to do so-at least on favorable terms.
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Surrogates are also not invested with the same public duty as their related academic institutions. Their duties, especially if they are publicly traded companies-as are Editas, Intellia, and Emmanuelle Charpentier's own company, CRISPR Therapeutics-are to their shareholders. 51 In both real and legal terms, this duty tacks toward profit maximization rather than, say, advancing scientific knowledge or public access to the downstream products of their research-ideals typically lauded by research institutions. 52 With respect to this conflict between public-facing goals and shareholder value, Michael Eisner, former CEO of Disney, put it best: 'We have no obligation to make history. We have no obligation to make art. We have no obligation to make a statement. To make money is our only objective'. 53 Lastly, surrogate licensing-even when functioning well-may 'bottleneck' the commercial development of the underlying technology. 54 Surrogates may grant exclusive sublicenses that are too broad relative to their licensees' contributions; this blocks others from developing competing technologies. 55 Surrogates may also grant licenses to disease indications or areas of the genome far greater than any sublicensee can work at any given time. 56 To be sure, bottlenecking is a serious problem with respect to university licensing as well. 57 But universities are frequently more invested in nonexclusive licenses to commercial developers than for-profit surrogates.
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ETHICAL LICENSING AND ENFORCEMENT
Most of the commentary on the CRISPR patents has been negative-and, in particular, the negative side of patenting the products of academic research.
59 But-aside from money-there are some significant social positives as well. At their core, patents 47 Id. 48 Id. at 700. 49 
r Patent protection for CRISPR
are rights to exclude others from practicing the claimed invention. 60 The corollary to this axiom is that patents therefore allow their owners to dictate to the rest of the world how to use the inventors' technology. 61 This power to direct others' research can be harnessed for societal good. 62 Where the claimed technology raises ethical or social concerns, patent holders have the right to tell their technologies' users to behave ethically and to provide access to downstream inventions. 63 In this sense, patents-when used well-can function as a powerful form of private governance. 64 This is certainly the case with CRISPR, the ethical and social issues of which have been explored at length. 65 One potentially problematic use of CRISPR is its use in 'gene drives', a daisy chain of genetic editing that essentially forces future generations to inherit and subsequently pass on only a single variant of a particular gene. 66 The concern, as detailed by Kevin Esvelt, is that gene drives, because they are forcibly heritable, become difficult to control once put in place. 67 Should later research find negative, unintended effects of the particular genetic variant driven through the population, it may simply be too late. 68 To that end, Esvelt and others have proposed patenting the use of CRISPR-based gene drives to, essentially, prevent others from using the technology without rigorous scientific and ethical controls. 69 The legal mechanics of enforcing patent protection in this manner leave some gaps that likely need to be addressed. But Esvelt's proposal suggests, at a minimum, that patenting controversial technologies is one possible tool to further their ethical use.
In other cases, rather than using patents to ethically restrict access to controversial technologies, patents can be used to ethically promote access to the same. That is, patent holders can demand licensees promise that they make their technology available to broad segments of society, and on fair terms. 70 This is largely the case with Monsanto's license from the Broad Institute covering the use of CRISPR-Cas9 for a variety of agricultural purposes. That license essentially requires Monsanto to allow its farmer customers to save and resew seed from one season to the next, in contrast to some of 'synthetic biology', famously abandoned patents as a tool for ethical governance in favor of standardized, contractual, materials transfer agreements-namely, the BioBrick User Agreement (BUA). 80 The BUA itself contains, in essence, ethical restrictions-notably, § 5, which prohibits 'intentionally harmful, negligent, or unsafe uses'. 81 While the enforceability of the agreement is questionable, it stands testament to the possibility of private ethical governance of platform technologies outside of patent assertion. In any event, the contrast among the WARF hESC patents, AddGene's BMTA, and the BUA demonstrates that, like CRISPR itself, patents are tools that can be used for good or for ill. At a minimum, ethically responsible patent pledges demonstrate the capacity of using patents as a tool for the public good.
CONCLUSIONS
In many ways, the ethical, legal, and social issues of CRISPR patenting are idiosyncratic. It is not often that a ground-breaking genetic engineering technology is invented, with monumental import to therapy, human reproduction, and social order. 82 And it is perhaps rarer still that such an important technology becomes the subject of a contentious patent dispute among some of the world's highest esteemed research institutions. Nonetheless-despite claims that the CRISPR patent dispute is a unique event-there are some greater lessons to be learned about the ethical, legal, and social implications of intellectual property in research science.
The first, and perhaps most important for day-to-day scientific practice, is that patents-their promises and pitfalls-should not ruin research collaborations. Science, and molecular biology in particular, is largely a team sport. 83 Researchers seeking to make the most significant advances in their fields must increasingly turn to others at the fringe of their disciplines for help. 84 In biology, this is perhaps best exemplified by the recent explosion of collaboration between molecular geneticists and computer scientists, the informational yields of which have been tremendous. 85 Even in the CRISPR context itself, it's worth reiterating that the two warring factions made their advances through collaborative efforts, despite patent disputes within research groups: Doudna with Charpentier; and Zhang with Luciano Marraffini of Rockefeller entirely on who's wielding them. To that end, the CRISPR patent controversies should encourage researchers to think about how, and by whom, their inventions will ultimately be used-both for those seeking to use them for good or for ill.
